Knight Therapeutics (GUD.TO)

Knight Therapeutics (GUD-T) has garnered mixed reviews from experts, highlighting its potential and the challenges it faces. One expert praises its value, noting the market's desire for more consistent earnings as it pursues a business model centered on acquiring 'orphaned' drugs. However, another expert warns that investors may find themselves stuck with the stock in their RRIF due to its inconsistent performance, despite good management. Currently, the stock is fluctuating between $5.75 and $6, with a possible drop to $5.14 if it cannot maintain its levels. While many technical indicators show the stock as oversold, there's no assurance of a rebound. Patience seems to be a recurring theme, as the company has shown positive trends over the past year, particularly in its Brazilian operations and expanding margins, making it one to watch for investors willing to endure volatility.